TABLE 4.
The result of ITS analysis of hepatitis B antiviral treatment nucleoside analogs medications in the “4 + 7”pilot cities.
| Categories | DDDs (ten thousand) | Expenditures (ten thousand CNY) | DDDc (CNY) | |||
|---|---|---|---|---|---|---|
| Coef. (95%C.I.) | p-value | Coef. (95%C.I.) | p-value | Coef. (95%C.I.) | p-value | |
| Selected medications | ||||||
| Baseline trend β 1 | 11.46 (−6.37,29.29) | 0.195 | 114.04 (28.02,200.06) | 0.012 | −0.10 (−0.16,-0.04) | 0.002 |
| Change in level β 2 | 618.41 (393.23,843.58) | <0.001 | −5273.84 (−6363.50,-4184.19) | <0.001 | −9.87 (−10.59,-9.15) | <0.001 |
| Change in slope β 3 | −9.37 (−43.76,25.02) | 0.576 | −276.83 (−442.85,-110.80) | 0.002 | −0.06 (−0.17,0.05) | 0.275 |
| Constant β 0 | 545.09 (409.59,680.59) | <0.001 | 7769.85 (7115.78,8423.91) | <0.001 | 14.53 (14.09,14.97) | <0.001 |
| Entecavir | ||||||
| Baseline trend β 1 | 6.93 (−8.17,22.02) | 0.350 | 54.53 (−16.91,125.97) | 0.127 | −0.01 (−0.05,0.03) | 0.523 |
| Change in level β 2 | 521.69 (330.93,712.44) | <0.001 | −4429.91 (−5334.85,-3524.98) | <0.001 | −9.50 (−10.00,-9.00) | <0.001 |
| Change in slope β 3 | −8.56 (−37.67,20.55) | 0.547 | −198.89 (−336.78,-60.99) | 0.007 | −0.12 (−0.20,-0.04) | 0.004 |
| Constant β 0 | 486.70 (372.00,601.40) | <0.001 | 7006.44 (6463.21,7549.66) | <0.001 | 13.17 (12.86,13.47) | <0.001 |
| Tenofovir Fumarate | ||||||
| Baseline trend β 1 | 4.53 (1.26,7.79) | 0.009 | 59.19 (41.20,77.17) | <0.001 | −0.09 (−0.15,-0.04) | 0.002 |
| Change in level β 2 | 97.92 (56.87,138.98) | <0.001 | −835.85 (−1063.56,-608.14) | <0.001 | −9.77 (−10.46,-9.08) | <0.001 |
| Change in slope β 3 | −1.05 (−7.36,5.25) | 0.731 | −78.31 (−113.00,-43.62) | <0.001 | −0.06 (−0.17,0.04) | 0.239 |
| Constant β 0 | 58.32 (33.47,83.17) | <0.001 | 764.40 (627.73,901.06) | <0.001 | 14.38 (13.96,14.80) | <0.001 |
| Alternative medications | ||||||
| Baseline trend β 1 | −2.90 (−4.47,-1.32) | 0.001 | −46.72 (−62.62,-30.83) | <0.001 | −0.11 (−0.14,-0.08) | <0.001 |
| Change in level β 2 | −12.25 (−32.16,7.66) | 0.214 | −82.83 (−283.49,117.83) | 0.399 | 0.22 (−0.17,0.60) | 0.253 |
| Change in slope β 3 | 1.12 (−1.93,4.16) | 0.453 | 24.29 (−6.36,54.95) | 0.114 | 0.07 (0.01,0.12) | 0.030 |
| Constant β 0 | 151.33 (139.34,163.31) | <0.001 | 1742.05 (1621.28,1862.82) | <0.001 | 11.54 (11.31,11.77) | <0.001 |
| Lamivudine | ||||||
| Baseline trend β 1 | −0.90 (−1.08,-0.72) | <0.001 | −27.82 (−32.21,-23.42) | <0.001 | −0.22 (−0.33,-0.12) | <0.001 |
| Change in level β 2 | 0.32 (−1.97,2.61) | 0.772 | 16.98 (−38.65,72.62) | 0.531 | 0.01 (−1.24,1.27) | 0.983 |
| Change in slope β 3 | 0.65 (0.30,1.00) | 0.001 | 21.17 (12.70,29.65) | <0.001 | 0.16 (−0.04,0.36) | 0.107 |
| Constant β 0 | 21.04 (19.66,22.41) | <0.001 | 595.56 (562.16,628.96) | <0.001 | 28.57 (27.78,29.37) | <0.001 |
| Adefovir dipivoxil | ||||||
| Baseline trend β 1 | −1.88 (−3.04,-0.73) | 0.003 | −16.66 (−24.04,-9.29) | <0.001 | −0.05 (−0.08,-0.02) | 0.001 |
| Change in level β 2 | −10.34 (−24.92,4.24) | 0.155 | −56.02 (−149.07,37.02) | 0.224 | −0.01 (−0.32,0.31) | 0.971 |
| Change in slope β 3 | 0.72 (−1.51,2.94) | 0.510 | 7.35 (−6.88,21.58) | 0.294 | 0.02 (−0.03,0.07) | 0.516 |
| Constant β 0 | 106.14 (97.37,114.92) | <0.001 | 705.00 (648.91,761.08) | <0.001 | 6.66 (6.47,6.86) | <0.001 |
| Telbivudine | ||||||
| Baseline trend β 1 | −0.13 (−0.53,0.26) | 0.494 | −2.81 (−10.05,4.43) | 0.427 | −0.02 (−0.02,-0.01) | <0.001 |
| Change in level β 2 | −1.98 (−6.97,3.00) | 0.417 | −37.04 (−127.92,53.84) | 0.405 | −0.08 (−0.18,0.01) | 0.087 |
| Change in slope β 3 | −0.25 (−1.02,0.52) | 0.502 | −4.03 (−18.01,9.94) | 0.554 | 0.02 (0.01,0.04) | 0.005 |
| Constant β 0 | 24.28 (21.26,27.31) | <0.001 | 445.36 (390.28,500.44) | <0.001 | 18.34 (18.28,18.39) | <0.001 |
| Nucleotide analogs | ||||||
| Baseline trend β 1 | 8.63 (−10.15,27.42) | 0.349 | 68.60 (−28.28,165.49) | 0.155 | −0.08 (−0.12,-0.03) | 0.003 |
| Change in level β 2 | 605.49 (368.19,842.80) | <0.001 | −5364.88 (−6592.21,-4137.55) | <0.001 | −8.90 (−9.49,-8.32) | <0.001 |
| Change in slope β 3 | −8.40 (−44.62,27.83) | 0.634 | −254.21 (−441.18,-67.23) | 0.010 | −0.08 (−0.17,0.01) | 0.082 |
| Constant β 0 | 696.04 (553.29,838.79) | <0.001 | 9501.70 (8765.08,10,238.31) | <0.001 | 13.75 (13.39,14.10) | <0.001 |
ITS: interrupted time series; NAs: Nucleoside Analogs; DDDs: Defined Daily Doses; DDDc: Defined Daily Drug cost; CNY: Chinese Yuan. The bold value meaning was classification of antiviral medications of hepatitis B virus in this study.